









Markets
/
Stocks
/
nasdaq-cmnd
/

Clearmind Medicine Inc

CMND

1.190USD

+0.185+18.41%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

6.40MMarket Cap

LossP/E TTM



Clearmind Medicine Inc

1.190

+0.185+18.41%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

309 / 506

Overall Ranking

604 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 15 patent families, including 27 granted patents and 24 pending applications. The portfolio spans a range of jurisdictions, including the United States, Europe, India, and China.

Undervalued

The company’s latest PE is -1.06, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 768.21K shares, decreasing 41.21% quarter-over-quarter.

Held by Joel Greenblatt

Star Investor Joel Greenblatt holds 344.52K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.89, which is -1.00% below the recent high of -0.88 and -12.44% above the recent low of -1.00.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 309/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 1.18, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.06 and the support level at 0.96, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.18

Change

0.41

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MACD(12,26,9)

0.016

Buy

RSI(14)

70.546

Buy

STOCH(KDJ)(9,3,3)

43.297

Buy

ATR(14)

0.058

High Vlolatility

CCI(14)

442.499

Overbought

Williams %R

37.523

Buy

TRIX(12,20)

0.102

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.049

Buy

MA10

1.038

Buy

MA20

1.032

Buy

MA50

1.020

Buy

MA100

0.986

Buy

MA200

1.121

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 14.28%, representing a quarter-over-quarter decrease of 1.95%. The largest institutional shareholder is Joel Greenblatt, holding a total of 344.52K shares, representing 6.40% of shares outstanding, with 18.13% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Gotham Asset Management, LLC

Star Investors

343.43K

+0.16%

AdvisorShares Investments, LLC

205.93K

-6.79%

Shani (Adi Zuloff)

54.23K

+3153.45%

Weiss (Amitay)

39.83K

-27.76%

Rootenberg (Alan)

24.75K

+161.59%

Cornerstone Wealth Group, LLC

20.00K

Shachar (Yehonatan Samuel)

12.50K

Itzhaik (Asaf)

12.50K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.23, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -1.24. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.